Navigation Links
First cGMP feeder-independent pluripotent stem cell banks released for distribution
Date:7/7/2009

MADISON The WiCell Research Institute and the Waisman Clinical Biomanufacturing Facility (WCBF) announced today (July 6) the release of the first current Good Manufacturing Practices (cGMP) feeder-independent pluripotent stem cell banks available for sale and distribution to researchers worldwide.

These cGMP banks of human embryonic stem (ES) cells are produced using H9 (WA09), one of the original lines derived by stem cell pioneer James Thomson at the University of Wisconsin-Madison and the most frequently used and cited human ES cell line in stem cell research today. Release of this material demonstrates the successful execution of the production, quality-control testing and documentation required for cGMP banks.

Through the new partnership between WiCell and the WCBF, researchers now can purchase matched cGMP and research cell banks, allowing them the opportunity to seamlessly advance their programs from research through clinical application. In the future, WiCell and the WCBF plan to make available a wide variety of other cGMP lines, including lines produced from newly derived, fully compliant human ES cells and induced pluripotent stem (iPS) cells. These clinical-grade cell banks will help advance the field of regenerative medicine.

"The effective development of stem cell-based therapeutics requires cell banks that have been characterized and produced under conditions suitable for human clinical trials," says Thomson, director of regenerative biology at the new private Morgridge Institute for Research at UW-Madison and the scientific director of WiCell. "The availability of these cGMP stem cell banks and matched research cell lines should open the door to more rigorous, reliable and successful clinical applications."

"The availability of stem cell banks that have been produced and tested under cGMP is a critical component of any program that intends to advance a stem cell-based therapy into human clinical trials," says Erik Forsberg, executive director of WiCell. "Using matched research/cGMP stem cell banks early in development will greatly reduce the time and cost associated with transitioning research projects from bench to bedside."

The collaboration between two leading organizations in the stem cell field, the WiCell Research Institute and the Waisman Clinical Biomanufacturing Facility, is key to the successful production of cGMP stem cell products. Human embryonic stem cells cultured and propagated at WiCell serve as the source of the well-characterized research cell banks. Production of clinical master cell banks then is carried out in the WCBF cleanrooms with complete cGMP testing and documentation. Cell banks are offered as research banks derived from the cGMP master cell bank for screening cell properties, as well as cGMP working cell banks, derived from the same fully tested master cell bank under cGMP conditions.

Derek Hei, director of the WCBF, says, "It is a priority of our partnership with WiCell to pursue cGMP feeder-independent production of both human ES and iPS cells. We need to continue work with both cell types until we more thoroughly understand their characteristics and how these characteristics may affect their potential use in therapies."

"cGMP stem cell banks represent the key in today's research market with respect to therapeutics, clinical applications and human clinical trials," says Clive Svendsen, director of Cedars-Sinai Regenerative Medicine Institute, Los Angeles. "For scientists poised to take their research to new levels and explore the reality of using pluripotent stem cells to cure human disease, the tools now provided through this partnership between WiCell and the WCBF signal the beginning of a new era in regenerative medicine."


'/>"/>

Contact: Janet L. Kelly
jkelly@warf.org
608-890-1491
University of Wisconsin-Madison
Source:Eurekalert

Related biology news :

1. Which came first, the moth or the cactus?
2. First all-African GM crop is resistant to maize streak virus
3. Scientists retrace evolution with first atomic structure of an ancient protein
4. CU-Boulder team discovers first ancient manioc fields in Americas
5. First finding of a metabolite in 1 sex only
6. First orchid fossil puts showy blooms at some 80 million years old
7. First individual genome sequence published
8. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
9. UNH becomes first university in nation to use landfill gas as primary energy source
10. Scientists in first global study of poison gas in the atmosphere
11. Weight gain between first and second pregnancies associated with increased odds of male second child
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., ... Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of the ... deploys the CANARY® test platform for the detection of harmful pathogens, including a ...
(Date:4/27/2016)... April 27, 2016 MedDay, a biotechnology ... announces the appointment of Catherine Moukheibir as Chairman of its ... Chairman, Jean Jacques Garaud , who contributed to the ... effective immediately. Catherine started her career in strategy ... and London .  She held C-Suite level ...
(Date:4/26/2016)... CAMBRIDGE, Mass. (PRWEB) , ... April 26, 2016 , ... ... Herr has been selected as one of three finalists for the European Inventor ... the EPO’s annual innovation prize will be announced at a ceremony in Lisbon on ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
Breaking Biology Technology: